Clinical and Microbiological Characterization of Late Breast Implant Infections after Reconstructive Breast Cancer Surgery
Abstract
Background: Implant infections represent a relevant problem after immediate breast cancer reconstruction. In addition to difficulties in distinguishing early infections from other post-surgical complications (such as hematoma, seroma, and liponecrosis) late breast implant infections still represent a grey area of our knowledge with regards to heir definition and management. To address this issue, we prospectively monitored breast cancer patients at their center.
Methods: Between February 1, 2009, and May 31, 2013, we enrolled all patients undergoing breast implant reconstruction or expander-to-prosthesis substitution. Patients without at least 6 mo of post-operative observation were excluded. We collected data from patient records including age, days from surgery (DFS), chemotherapy/radiotherapy, infecting microorganism, type of implant, antibiotic management and eventual implant removal. Sixty days from surgery were defined as the clinical threshold between early and late infection. Infections were further classified according to a graded scale into possible, probable and microbiologically proved.
Results: Seventy-eight infections were recorded out of 766 surgical procedures (10.2%). Fifty-three (67%) cases occurred early ≤60 DFS, and 25 (33%) occurred late (i.e., beyond 60 d). By defining infection types as possible, probable or proved, the majority of late infections were classified as proved (84%) compared with 56% of early infections (p=0.0014). Microbiological isolate distribution was similar in proved early infections compared with proved late infections. Among late infections, a delayed occurrence was observed after prosthesis placement compared with expander insertion. Late infections were fraught with lower treatment success rates (12% vs. 41%, p=0.009).
Conclusion: Late infection represents a consistent proportion of infections after immediate breast implant reconstruction or prosthesis placement and bear lower chance of salvage after treatment. An increased attention is warranted to improve prevention and treatment strategies.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Washer LL, Gutowski K. Breast implant infections. Infect Dis Clin North Am 2012;26:111–125.
2.
Franchelli S, Vassallo F, Porzio C, et al. Breast implant infections after surgical reconstruction in patients with breast cancer: Assessment of risk factors and pathogens over extended post-operative observation. Surg Infect. 2012;13:154–158.
3.
Craft RO, Damjanovic B, Colwell AS. Evidence-based protocol for infection control in immediate implant-based breast reconstruction. Ann Plastic Surg 2012;69:446–450
4.
Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis 2005;5:94–106.
5.
Weichman KE, Levine SM, Wilson SC, et al. Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction. Ann Plast Surg 2013;71:140–143.
6.
Olsen MA, Mellani L, Dietz JR et al. Risk factors for surgical site infection following major breast surgery. J Am Coll Surg 2008;207:326–335.
7.
Throckmorton AD, Baddour LM, Hoskin TL et al. Microbiology of surgical site infections complicating breast surgery. Surg Infect 2010;11:355–359.
8.
Lankiewicz JD, Yokoe DS, Olsen MA et al. Beyond 30 days: Does limiting the duration of surgical site infection follow-up limit detection? Infect Control Hosp Epidemiol 2012;33:202–204.
9.
Brahmbhatt R, Huebner M, Scow J, et al. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: Survey of the american society of breast surgeons. Ann Surg Oncol 2012;19: 3205–3211.
10.
Nicolas P, Yazdan Y, Marie-Pierre C, et al. Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. J Surg Oncol 2007;96:124–129.
11.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36: 309–332.
12.
Trampuz A, Zimmerli W. Prosthetic joint infections: Update in diagnosis and treatment. Swiss Med Wkly 2005;135:243–251.
13.
Zetrenne E, McIntosh BC, McRae MH, et al. Prosthetic vascular graft infection: A multi-center review of surgical management. Yale J Biol Med 2007;80:113–121.
14.
Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The task force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC). European Heart Journal 2009;30:2369–2413.
15.
Chang J, Lee GW. Late hematogenous bacterial infections of breast implants: Two case reports of unique bacterial infections. Ann Plastic Surg 2011;67:14–16
16.
Brand KG. Infection of mammary prostheses: A survey and the question of prevention. Ann Plast Surg 1993;30:289–295.
17.
Hunter JG, Padilla M, Cooper-Vastola S. Late clostridium perfringens breast implant infection after dental treatment. Ann Plast Surg 1996;36:309–312.
18.
Prince MD, Suber JS, Aya-Ay ML et al. Prosthesis salvage in breast reconstruction patients with periprosthetic infection and exposure. Plast Reconstr Surg 2012;129:42–48.
19.
Hvilsom GB, Hölmich LR, Steding-Jessen M et al. Delayed breast implant reconstruction: A 10-year prospective study. J Plast Reconstr Aesthet Surg 2011;11:1466–1474.
20.
Francis SH, Ruberg RL, Stevenson KB et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg 2009;124:1790–1796.
21.
Halvorson EG, Disa JJ, Mehrara BJ et al. Outcome following removal of infected tissue expanders in breast reconstruction: A 10-year experience. Ann Plastic Surg 2007;59:131–136.
22.
Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections perioperative antimicrobial regimens. Infect Control Hosp Epidemiol 2014;35:75–81.
23.
Miller TA. Modern Surgical Care 3rd ed. St Louis: Quality Medical; 2006:149.
24.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
25.
Performance standards for antimicrobial disk susceptibility tests; approved standard eleventh edition; replaces m02-a10 vol. 29 no. 1. Clinical and Laboratory Standards Institute (CLSI) 2012;32.
26.
Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006;48: e1–e148.
27.
Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the infectious diseases society of america. Clin Infect Dis 2013;56:1–25.
28.
Baddour LM, Cha Y-M, Wilson WR. Clinical practice. Infections of cardiovascular implantable electronic devices. N Engl J Med 2012;367:842–849.
29.
Lentz R, Ng R, Higgins SA, et al. Radiation therapy and expander-implant breast reconstruction: An analysis of timing and comparison of complications. Ann Plastic Surg 2013;71:269–273.
30.
Ascherman JA, Hanasono MM, et al. Implant reconstruction in breast cancer patients treated with radiation therapy. Plast Reconstr Surg 2006;117:359–365.
31.
Bjerke-Kroll BT, Christ AB, McLawhorn AS, et al. Periprosthetic joint infections treated with two-stage revision over 14 years: An evolving microbiology profile. J Arthroplasty 2014;29:877–882.
32.
Greenspon AJ, Rhim ES, Mark G, et al. Lead-associated endocarditis: The important role of methicillin-resistant Staphylococcus aureus. Pacing Clin Electrophysiol 2008;31:548–553.
33.
Tayebjee MH, Joy ER, Sandoe JA. Can implantable cardiac electronic device infections be defined as ‘early’ or ‘late’ based on the cause of infection? J Med Microbiol 2013;62:1215–1219.
34.
Kuiper JW, Vos SJ, Saouti R, et al. Prosthetic joint-associated infections treated with dair (debridement, antibiotics, irrigation, and retention): Analysis of risk factors and localantibiotic carriers in 91 patients. Acta Orthop 2013;84:380–386.
35.
Bose B. Delayed infection after instrumented spine surgery: Case reports and review of the literature. Spine J 2003;3:394–399.
36.
Brown M, Drinkwater C. Hematogenous infection of total hip arthroplasty with actinomyces following a noninvasive dental procedure. Orthopedics. 2012;35:e1086–e1089.
37.
Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin in Infect Dis 2006;19:349–356
38.
Rethman MP WWr, Abt E, Anderson PA, et al; The American Academy of Orthopaedic Surgeons and the American Dental Association clinical practice guideline on the prevention of orthopaedic implant infection in patients undergoing dental procedures. J Bone Joint Surg Am 2013;95: 745–747.
39.
Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis. Guidelines from the American Heart Association. A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and The Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736–1754.
Information & Authors
Information
Published In
Copyright
Copyright 2015, Mary Ann Liebert, Inc.
History
Published online: 5 October 2015
Published in print: October 2015
Published ahead of print: 14 July 2015
Topics
Authors
Author Disclosure Statement
All authors concurred to the work and approved the manuscript. There are no conflicts of interest for all authors actual or potential. No outside funding was received.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.